<DOC>
	<DOCNO>NCT00595335</DOCNO>
	<brief_summary>This study do investigate effect ( good bad ) Rituximab treatment autoimmune eye disease call Graves ' ophthalmopathy . This disease proven difficult treat . Rituximab monoclonal antibody deplete line cell involve autoimmune response . The study hypotheses rituximab effective treatment patient moderate severe active Graves ' ophthalmopathy .</brief_summary>
	<brief_title>Trial Rituximab Graves ' Ophthalmopathy</brief_title>
	<detailed_description>Laboratory evidence suggest autoantibody target thyrotropin receptor directly involve pathogenesis Graves ' ophthalmopathy ( GO ) . This double-blind , randomize , control study determine whether rituximab , anti-B-lymphocyte antigen ( CD20 ) monoclonal antibody induce transient B-cell depletion , effective treatment moderate severe , active GO . Before treatment give , careful eye thyroid physical examination perform patient several thyroid blood test , test count white cell blood , CT scan head eye . A close-up photograph face take patient give short questionnaire eye feel eye disease affect quality life . Each study subject receive either 2 infusion rituximab ( 1000 mg ; give 2 week apart ) 2 intravenous infusion saline . Glucocorticoids ( methylprednisolone 100 mg ) saline also administer IV premedication rituximab placebo arm respectively , blind fashion match randomization , decrease rate infusion-associated reaction . All antihypertensive medication hold 12 hour prior infusion . Patients return 2 week first intravenous infusion order receive second infusion . Patients assess week 8 , 16 , 24 52 eye disease severity , CAS , thyroid stimulate hormone ( TSH ) , free thyroxine ( fT4 ) , free triiodothyronine ( fT3 ) , thyroid autoantibody ( TRAB ) , thyroid peroxidase ( TPO ) C19+B cell count . CT scan orbit obtain baseline week 52 orbital volume measurement proptosis . Thyroid ultrasound obtain baseline , week 24 week 52 thyroid volume measurement color Doppler flow assessment . Data analysis - Continuous variable compare two treatment group use test Wilcoxon rank sum test , categorical variable analyze use chi-square /Fisher exact test . Non-parametric method use throughout normality chi-squared assumption hold . General linear model use access treatment effect change CAS baseline 24 52 week . Patients discontinue trial prior week 52 evaluated discontinuation data carry forward either 24 week ( 5 patient discontinue prior week 24 ) 52 week ( single patient discontinue trial 24 week ) final evaluation patient . A p-value &lt; 0.05 consider significant .</detailed_description>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Graves Ophthalmopathy</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Patients clinical activity score ( CAS ) â‰¥4 moderate severe disease severity , define thyroid eye disease severity scale base first letter define characteristic class , classification know : 'no sign symptom ; sign ; soft tissue ; proptosis ; extraocular muscle ; cornea ; sight loss ' ( NOSPECS ) score Euthyroid least 68 week No immediate need decompression surgery With disease progression previous 12 month without evident improvement prior 6 month . Corticosteroid use precede 4 week HIV , hepatitis C hepatitis B infection Denied consent HIV hepatitis test Mild inactive Graves ' ophthalmopathy Orbital radiotherapy within 18 month orbital surgery within past year Absolute neutrophil count &lt; 1,500/mm^3 Pregnant nursing patient Coronary artery disease , congestive heart failure , significant arrhythmia , significant infection immunodeficiency , serious illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Thyroid-associated ophthalmopathy</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Proptosis</keyword>
</DOC>